Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

∂-Opioid Receptor Antibodies

Close filters
No results were found for the filter!
Citations
Agonist-induced Threonine361 phosphorylation of the δ-Opioid Receptor.
pT361-DOP (phospho-∂-Opioid Receptor Antibody)
Threonine361 (T361) is a major phosphorylation site of the delta-opioid receptor (DOP). The pT361-DOP antibody detects phosphorylation in response to agonists but not after PKC activation. T361 phosphorylation is a key regulator of DOP...
$ 375.00 *
Details
Citations
Agonist-induced Serine363 phosphorylation of the δ-Opioid receptor.
pS363-DOP (phospho-∂-Opioid Receptor Antibody)
Serine363 (S363) is the primary phosphorylation site in a hierarchical phosphorylation cascade of the delta-opioid receptor (DOP). The pS363-DOP antibody detects phosphorylation in response to high- and low-efficacy agonists but not...
$ 375.00 *
Details
NEW
Validation of the δ-Opioid Receptor in transfected HEK293 cells
DOP (non-phospho) ∂-Opioid Receptor Antibody
The non-phospho-∂-opioid receptor antibody is directed against the distal end of the carboxyl-terminal tail of mouse, rat and human DOP. It can be used to detect total DOP receptors in Western blots independent of phosphorylation.
$ 300.00 *
Details
NEW
Agonist-induced Threonine358/Threonrine361 phosphorylation of the δ-Opioid receptor
pT358/pT361-DOP (phospho-∂-Opioid Receptor...
Threonine358/Threonine361 (T358/T361) is the primary phosphorylation site in a hierarchical phosphorylation cascade of the delta-opioid receptor (DOP). The pT358/T361-DOP antibody detects phosphorylation in response to high- and...
$ 375.00 *
Details
NEW
Agonist-induced Threonine361/Serine363 phosphorylation of the δ-Opioid receptor
pT361/pS363-DOP (phospho-∂-Opioid Receptor...
Threonine361/Serine363 (T361/S363) is the primary phosphorylation site in a hierarchical phosphorylation cascade of the delta-opioid receptor (DOP). The pT361/pS363-DOP antibody detects phosphorylation in response to high- and...
$ 375.00 *
Details

DOP

Activation of the δ-opioid receptor (delta-opioid receptor, DOP) results in analgesic, antidepressant and anxiolytic effects in a number of animal models. Whereas high-efficacy DOP agonists such as SNC80 also produce convulsions, low-efficacy DOP agonists such ARD-353 or ARM100390 do not. The cyclic enkephalin analog DPDPE (H-Tyr-c[D-Pen-Gly-Phe-D-Pen]) is used as selective δ-agonist for in vitro studies. DOP desensitization, trafficking and signaling are regulated by phosphorylation of carboxyl-terminal threonine361 (pT361-DOP) and serine363 (pS363-DOP) residues. S363 is the primary site in a hierarchical phosphorylation cascade. Both T361 and S363 can be phosphorylated by GRK2 and GRK3 but not by PKC. This nomenclature refers to the human DOP. The sequence of this phosphorylation motif is highly conserved in mice, rats and humans. For more information on δ-opioid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Mann A, Liebetrau S, Klima M, Dasgupta P, Massotte D, Schulz S. Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies. Sci Rep. 2020 May 22;10(1):8585. doi: 10.1038/s41598-020-65589-7. PMID: 32444688

Gendron L, Cahill CM, von Zastrow M, Schiller PW, Pineyro G. Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev. 2016 Jul;68(3):631-700. doi: 10.1124/pr.114.008979. Review. PubMed PMID: 27343248; PubMed Central PMCID: PMC4931872.

Activation of the δ-opioid receptor (delta-opioid receptor, DOP) results in analgesic, antidepressant and anxiolytic effects in a number of animal models. Whereas high-efficacy DOP agonists... read more »
Close window
∂-Opioid Receptor Antibodies

DOP

Activation of the δ-opioid receptor (delta-opioid receptor, DOP) results in analgesic, antidepressant and anxiolytic effects in a number of animal models. Whereas high-efficacy DOP agonists such as SNC80 also produce convulsions, low-efficacy DOP agonists such ARD-353 or ARM100390 do not. The cyclic enkephalin analog DPDPE (H-Tyr-c[D-Pen-Gly-Phe-D-Pen]) is used as selective δ-agonist for in vitro studies. DOP desensitization, trafficking and signaling are regulated by phosphorylation of carboxyl-terminal threonine361 (pT361-DOP) and serine363 (pS363-DOP) residues. S363 is the primary site in a hierarchical phosphorylation cascade. Both T361 and S363 can be phosphorylated by GRK2 and GRK3 but not by PKC. This nomenclature refers to the human DOP. The sequence of this phosphorylation motif is highly conserved in mice, rats and humans. For more information on δ-opioid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Mann A, Liebetrau S, Klima M, Dasgupta P, Massotte D, Schulz S. Agonist-induced phosphorylation bar code and differential post-activation signaling of the delta opioid receptor revealed by phosphosite-specific antibodies. Sci Rep. 2020 May 22;10(1):8585. doi: 10.1038/s41598-020-65589-7. PMID: 32444688

Gendron L, Cahill CM, von Zastrow M, Schiller PW, Pineyro G. Molecular Pharmacology of δ-Opioid Receptors. Pharmacol Rev. 2016 Jul;68(3):631-700. doi: 10.1124/pr.114.008979. Review. PubMed PMID: 27343248; PubMed Central PMCID: PMC4931872.

Recently viewed